Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Net Margin: 2021-2025

Historic Net Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to -10.69%.

  • Tarsus Pharmaceuticals' Net Margin rose 3813.00% to -10.69% in Q3 2025 from the same period last year, while for Sep 2025 it was -22.13%, marking a year-over-year increase of 8031.00%. This contributed to the annual value of -63.16% for FY2024, which is 71573.00% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Net Margin of -10.69% as of Q3 2025, which was up 45.68% from -19.67% recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Net Margin registered a high of 3,853.99% during Q2 2023, and its lowest value of -4,286.98% during Q4 2021.
  • Moreover, its 3-year median value for Net Margin was -48.81% (2024), whereas its average is 14.76%.
  • In the last 5 years, Tarsus Pharmaceuticals' Net Margin soared by 478,862bps in 2022 and then crashed by 563,217bps in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Net Margin (Quarterly) stood at -4,286.98% in 2021, then skyrocketed by 415,072bps to -136.26% in 2022, then slumped by 18,846bps to -324.72% in 2023, then soared by 28,996bps to -34.76% in 2024, then spiked by 3,813bps to -10.69% in 2025.
  • Its Net Margin was -10.69% in Q3 2025, compared to -19.67% in Q2 2025 and -31.96% in Q1 2025.